

# Toxicological Profile for Bromodichloromethane

**March 2020** 



BROMODICHLOROMETHANE

## **DISCLAIMER**

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

#### **FOREWORD**

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH

Director, National Center for Environmental Health and Agency for Toxic Substances and Disease Registry Centers for Disease Control and Prevention

takele Bragge

BROMODICHLOROMETHANE in

### \*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

BROMODICHLOROMETHANE

# **VERSION HISTORY**

Date	Description
March 2020	Final toxicological profile released
April 2018	Draft for public comment toxicological profile released
December 1989	Final toxicological profile released

BROMODICHLOROMETHANE v

#### **CONTRIBUTORS & REVIEWERS**

#### **CHEMICAL MANAGER TEAM**

Susan Zells Ingber, A.B., M.S.P.P. (Lead) Lisa Ingerman, Ph.D., D.A.B.T.

Melanie Buser, M.P.H. Christina Coley, B.S. Mario Citra, Ph.D.

Fernando Llados, Ph.D. Laura A. McIlroy, B.A.

ATSDR, Division of Toxicology and Human Health

Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

#### **REVIEWERS**

## **Interagency Minimal Risk Level Workgroup:**

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

## Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, National Center for Environmental Assessment.

#### PEER REVIEWERS

- 1. Bill L. Lasley, Ph.D., Center for Health and Environment, University of California, Davis, California:
- 2. David Savitz, Ph.D., Brown University, Providence, Rhode Island; and
- 3. June K. Dunnick, Ph.D., NIEHS, Research Triangle Park, North Carolina.

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

# **CONTENTS**

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	X
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	
1.1 OVERVIEW AND U.S. EXPOSURES	
1.2 SUMMARY OF HEALTH EFFECTS	
1.3 MINIMAL RISK LEVELS (MRLs)	
CHAPTER 2. HEALTH EFFECTS	
2.1 INTRODUCTION	
2.1 INTRODUCTION	
2.3 BODY WEIGHT	
2.4 RESPIRATORY	
2.5 CARDIOVASCULAR	
2.6 GASTROINTESTINAL	
2.7 HEMATOLOGICAL	
2.8 MUSCULOSKELETAL	
2.9 HEPATIC	
2.10 RENAL	61
2.11 DERMAL	62
2.12 OCULAR	62
2.13 ENDOCRINE	63
2.14 IMMUNOLOGICAL	63
2.15 NEUROLOGICAL	64
2.16 REPRODUCTIVE	64
2.17 DEVELOPMENTAL	
2.18 OTHER NONCANCER	70
2.19 CANCER	
2.20 GENOTOXICITY	72
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICA	<b>L</b>
INTERACTIONS	
3.1 TOXICOKINETICS	
3.1.1 Absorption	77
3.1.2 Distribution	78
3.1.3 Metabolism	79
3.1.4 Excretion	
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	
3.1.6 Animal-to-Human Extrapolations	
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	
3.3.1 Biomarkers of Exposure	84

3.3.2 Biomarkers of Effect	
3.4 INTERACTIONS WITH OTHER CHEMICALS	86
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	87
4.1 CHEMICAL IDENTITY	
4.2 PHYSICAL AND CHEMICAL PROPERTIES	
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	
5.1 OVERVIEW	
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	
5.2.1 Production	
5.2.3 Use	
5.2.4 Disposal	
5.3 RELEASES TO THE ENVIRONMENT	91
5.3.1 Air	
5.3.2 Water	
5.3.3 Soil	
5.4 ENVIRONMENTAL FATE	
5.4.1 Transport and Partitioning	
5.4.2 Transformation and Degradation	
5.5 LEVELS IN THE ENVIRONMENT	96
5.5.1 Air	98
5.5.2 Water	
5.5.3 Sediment and Soil	
5.5.4 Other Media	
5.6 GENERAL POPULATION EXPOSURE	
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	116
CHAPTER 6. ADEQUACY OF THE DATABASE	121
6.1 INFORMATION ON HEALTH EFFECTS	
6.2 IDENTIFICATION OF DATA NEEDS	121
6.3 ONGOING STUDIES	127
CHAPTER 7. REGULATIONS AND GUIDELINES	128
CHAPTER 8. REFERENCES	130
ADDENDICEG	
APPENDICES APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS	A 1
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS	
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR BROMODICHLOROMETHANE APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS	
DATA FOR BROMODICHLOROMETHANE	
APPENDIX D. USER'S GUIDE	
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	F-1
APPENDIX F. GLOSSARY	
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	
,	_

BROMODICHLOROMETHANE i:

# **LIST OF FIGURES**

1-1.	Health Effects Found in Animals Following Oral Exposure to Bromodichloromethane	3
1-2.	Summary of Sensitive Targets of Bromodichloromethane – Inhalation	6
1-3.	Summary of Sensitive Targets of Bromodichloromethane – Oral	7
2-1.	Overview of the Number of Studies Examining Bromodichloromethane Health Effects	12
2-2.	Levels of Significant Exposure to Bromodichloromethane – Inhalation	23
2-3.	Levels of Significant Exposure to Bromodichloromethane – Oral	50
5-1.	Number of NPL Sites with Bromodichloromethane Contamination	89
6-1.	Summary of Existing Health Effects Studies on Bromodichloromethane By Route and Endpoint	122

BROMODICHLOROMETHANE

# **LIST OF TABLES**

1-1.	Minimal Risk Levels (MRLs) for Bromodichloromethane	8
2-1.	Health Effects in Humans Exposed to Bromodichloromethane (BDCM)	13
2-2.	Levels of Significant Exposure to Bromodichloromethane – Inhalation	21
2-3.	Levels of Significant Exposure to Bromodichloromethane – Oral	25
2-4.	Genotoxicity of Bromodichloromethane In Vitro	72
2-5.	Genotoxicity of Bromodichloromethane In Vivo	74
3-1.	Tissue to Blood Ratios of Radioactivity 24-Hours After Gavage Administration of [14C]-Bromodichloromethane to Male Rats	79
4-1.	Chemical Identity of Bromodichloromethane	87
4-2.	Physical and Chemical Properties of Bromodichloromethane	88
5-1.	Lowest Limit of Detection Based on Standards	97
5-2.	Summary of Environmental Levels of Bromodichloromethane	97
5-3.	Bromodichloromethane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	97
5-4.	Percentile Distribution of Annual Mean Bromodichloromethane Concentrations (ppbv) Measured in Ambient Air at Locations Across the United States	98
5-5.	Statistical Summary of Bromodichloromethane Concentrations from the 2012 and 2013 National Monitoring Program	99
5-6.	Outdoor Air Monitoring Data for Bromodichloromethane	99
5-7.	Indoor Air Monitoring Data for Bromodichloromethane	100
5-8.	Water-Related Activities and Indoor Air Monitoring Data for Bromodichloromethane	101
5-9.	Surface Water Monitoring Data for Bromodichloromethane	102
5-10	). Groundwater Monitoring Data for Bromodichloromethane	104
5-11	. Drinking Water Monitoring Data for Bromodichloromethane	105
5-12	2. Swimming Pool Water Monitoring Data for Bromodichloromethane	107
5-13	8. Bromodichloromethane Detections in Food from the U.S. Food and Drug Administration (FDA) 1991–2003 Market Basket Survey	108
5-14	Bromodichloromethane in Food	110
5-15	5. Blood Bromodichloromethane Levels in the NHANES U.S. Population	113

BROMODICHLOROMETHANE xi

5-16.	Exposure and Blood Concentrations	117
5-17.	Exposure and Breath (Alveolar Air) Concentrations	119
5-18.	Exposure and Urine Concentrations	120